Levin Capital Strategies’s Prime Medicine PRME Stock Holding History

Levin Capital Strategies’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.4K	Hold	15,000	–	–	﹤0.01%	261
2026 Q1	$52.2K	Hold	15,000	–	–	﹤0.01%	230
2025 Q4	$52K	Hold	15,000	–	–	﹤0.01%	211
2025 Q3	$83.1K	Sell	15,000 -125,000	-89%	-$508K	0.01%	211
2025 Q2	$346K	Buy	140,000 +105,000	+300%	+$162K	0.03%	144
2025 Q1	$69.7K	Sell	35,000 -40,000	-53%	-$102K	0.01%	173
2024 Q4	$219K	Buy	75,000 +45,000	+150%	+$158K	0.02%	189
2024 Q3	$116K	Buy	+30,000	New	+$139K	0.01%	209
2024 Q2	–	Sell	-26,500	Closed	-$186K	–	260
2024 Q1	$186K	Buy	26,500 +6,500	+33%	+$49.3K	0.02%	203
2023 Q4	$177K	Buy	+20,000	New	+$154K	0.02%	214
2023 Q3	–	Sell	-20,000	Closed	-$293K	–	305
2023 Q2	$293K	Buy	+20,000	New	+$279K	0.03%	180
2023 Q1	–	Sell	-10,585	Closed	-$197K	–	266
2022 Q4	$197K	Buy	+10,585	New	+$191K	0.03%	189

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Levin Capital Strategies's PRME Position: Q2 2026 in Review

Levin Capital Strategies held its Prime Medicine (PRME) position steady in Q2 2026 at 15,000 shares worth $55.4K. The position accounts for ﹤0.01% of the portfolio, ranked #261.

Levin Capital Strategies first reported a position in PRME in Q4 2022 and has held it in 12 quarters since. The position peaked at $346K in Q2 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

Levin Capital Strategies held 15,000 shares of Prime Medicine worth $55.4K as of Q2 2026.
Levin Capital Strategies left its Prime Medicine share count unchanged in Q2 2026.
Prime Medicine made up ﹤0.01% of Levin Capital Strategies's portfolio in Q2 2026, its #261 holding.
Levin Capital Strategies first reported a position in Prime Medicine in Q4 2022 and has held it in 12 quarters since.
Levin Capital Strategies's Prime Medicine position peaked at $346K in Q2 2025.
188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.